Summary
- Novavax's share price drought spurred NASDAQ delisting notice.
- This simple stratagem puts Novavax back in business with a semi-respectable sales price of >$5.00.
- Will the pain for Novavax shareholders ever stop?
- I recommend that investors evaluate the company's reverse split as simply an exercise in reloading its gun for further dilution to come.
Novavax (NVAX) has been laboring mightily for ~30 years to position itself in the danger zone where it can test its skills at launching an FDA-approved therapy. Its recent 20:1 stock split somewhat muddies the picture. However, I remain quite bearish on the stock.
Novavax share price drought spurred NASDAQ delisting notice
Novavax's 2/28/19 announcement of its trial failure for ResVax to protect infants via maternal immunization against RSV disease knocked the legs out from beneath the shares per its stock price chart below:
Data by YCharts
